Spyre Therapeutics, Inc. (SYRE)
Automate Your Wheel Strategy on SYRE
With Tiblio's Option Bot, you can configure your own wheel strategy including SYRE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SYRE
- Rev/Share 0.0
- Book/Share 1.3946
- PB 12.168
- Debt/Equity 0.0
- CurrentRatio 8.0615
- ROIC -0.4296
- MktCap 1024200592.0
- FreeCF/Share -0.4909
- PFCF -6.0296
- PE -28.1064
- Debt/Assets 0.0
- DivYield 0
- ROE -0.491
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 2
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | SYRE | Leerink Partners | -- | Outperform | -- | $45 | April 8, 2025 |
| Initiation | SYRE | Wolfe Research | -- | Outperform | -- | $27 | March 18, 2025 |
News
Wall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics (SYRE): Here's What You Should Know
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Spyre Therapeutics (SYRE) points to a 244.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
How Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34%
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 258.3% in Spyre Therapeutics (SYRE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral
WALTHAM, Mass. , Feb. 25, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced that management will participate in the following upcoming investor conferences: Event: TD Cowen 45th Annual Healthcare Conference Format: Fireside chat and 1x1 meetings Date/Time: Tuesday, March 4, 2025 at 3:10pm ET Location: Boston, MA Event: Jefferies Biotech on the Beach Summit Format: 1x1 meetings Date: Tuesday, March 11, 2025 Location: Miami, FL Live audio webcasts and replays of the …
Read More
Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation
Published: February 19, 2025 by: PRNewsWire
Sentiment: Neutral
WALTHAM, Mass. , Feb. 19, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced a poster presentation at the 20th Congress of the European Crohn's and Colitis Organisation (ECCO), held February 19-22, 2025, in Berlin, Germany, showing that combined inhibition of α4β7 integrin and TL1A cytokine is superior to either monotherapy in mouse models of colitis and coadministration demonstrates no drug-drug effects on exposure in non-human primates (NHPs).
Read More
Can Spyre Therapeutics (SYRE) Climb 158.85% to Reach the Level Wall Street Analysts Expect?
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 158.9% upside potential for Spyre Therapeutics (SYRE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
About Spyre Therapeutics, Inc. (SYRE)
- IPO Date 2016-04-07
- Website https://www.spyre.com
- Industry Biotechnology
- CEO Dr. Cameron Turtle DPHIL, Ph.D.
- Employees 73